Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa trial of SM101 in systemic lupus erythematosus
NL-OMON37386Phase 2Withdrawn
- Sponsor
- Baxter International Inc.
- Start
- Nov 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of valziflocept in systemic lupus erythematosus (SLE) and lupus nephritis (LN) (3 arms), sponsored by Baxter International Inc. Primary endpoint: Safety parameters. Planned start Nov 2011; status: withdrawn.
02
Drugs
valziflocept
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NL-OMON37386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37386.